AiVita Biomedical is a medical company that develops commercial and clinical-stage programs utilizing curative and regenerative medicines. Its technologies include a Phase II-approved patient-specific immunotherapy for the treatment of ovarian cancer. The treatment, autologous dendritic cells loaded with autologous irradiated tumor cells, directs the patient’s own immune system to seek out and destroy the very cells responsible for the growth and spread of the disease. The company is also developing an immune monitoring technology to be used in conjunction with its immunotherapeutic approach.